The deal, expected to close in the first half of 2025, includes an upfront payment of $925m, with an additional $2.15bn contingent on meeting regulatory and sales milestones.

Anthos, founded in 2019 by Blackstone Life Sciences and Novartis, focuses on cardiovascular disease treatments. As part of its launch, the biotech firm secured the rights to abelacimab, an experimental anticoagulant designed to prevent blood clots. With this acquisition, Novartis is bringing abelacimab back into its development pipeline.

Abelacimab is currently undergoing Phase 3 clinical trials, with results anticipated in the second half of 2026. The acquisition aligns with Novartis’ broader strategy to expand its presence in cardiovascular medicine, a market with growing demand for advanced therapies.

Source: Yahoo Finance

If you think we missed any important news, please do not hesitate to contact us at news@pe-insights.com.